Diffuse large B-cell lymphoma

Decoding the Tumor Immune Microenvironment in Diffuse Large B-Cell Lymphoma: Prognostic Insights from CD163 and CD11c Profiling

By MedXY 08/11/2026

This study identifies distinct tumor immune microenvironment subgroups in diffuse large B-cell lymphoma based on CD163 and CD11c expression, revealing prognostic significance and potential therapeutic stratification with checkpoint inhibitors.

Hematology-Oncology news Pathology & Lab Medicine

Decoding CD79B Expression Gradient in Diffuse Large B-Cell Lymphoma: Implications for Germinal Center B-Cell Differentiation and Therapeutic Targeting

By MedXY 06/30/2026

CD79B expression in diffuse large B-cell lymphoma (DLBCL) exhibits a distinct gradient aligned with cell-of-origin subtypes and germinal center B-cell differentiation stages, highlighting the biological basis for differential therapy responses.

$Tisagenlecleucel for Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Clinical Outcomes and Long-Term Follow-Up from the JULIET Trial$

Clinical Updates Hematology-Oncology news

Tisagenlecleucel for Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Clinical Outcomes and Long-Term Follow-Up from the JULIET Trial

By MedXY 12/08/2025

Tisagenlecleucel CAR T-cell therapy demonstrates durable responses and manageable safety in adults with relapsed or refractory diffuse large B-cell lymphoma, with 5-year data supporting its curative potential in select patients.

Hematology-Oncology news

Enhancing Patient Experience in DLBCL: Insights from PROs and Clinician-Reported AEs in the Phase 3 POLARIX Trial

By MedXY 10/14/2025

The POLARIX trial demonstrates superior progression-free survival with Pola-R-CHP in untreated DLBCL, highlighting the utility of patient-reported outcomes alongside clinician-reported adverse events to capture symptom burden and quality of life comprehensively.